6) ... I speak from personal experience ... Is it partly to pay exorbitant salaries for BGE and Exelon executives? The Maryland Public Service Commission apparently has zero control over BGE, and this needs to be corrected immediately ... — Bob Rassa, Fallston ... .
BGE had announced job cuts in December but had not finalized numbers. The utility was negotiating with IBEW Local 410, which represents BGE’s unionized workers, but the parties failed to reach an agreement.
During a heated debate at a Public Service Commission hearing Wednesday morning, Baltimore Gas and Electric Co.’s (BGE) representatives agreed to share monthly data about their customer service center with state authorities.
A Maryland Public Service Commission investigation revealed these issues in December and said they point to “systemic failings” in BGE’s customer call center ... BGE’s plan draws criticism.
Maryland families are opening their utility bills every month and asking the same question. Why is this getting so expensive?. The answer isn’t the weather. It isn’t increased usage. And it certainly isn’t accidental. It’s policy ... bill ... And it gets worse ... .
After one of the most intense winter storms to hit Maryland in recent years, BGE's electric system delivered strong, reliable performance - with only minimal outages across Maryland ... BGE's ongoing work ...
In fact, the bill was significantly higher than any bill he had every gotten from BGE, he said ... His electric and gas bill from BGE has been creeping higher in recent years, despite his household’s efforts to limit electricity and gas use.
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026 ... Anticipated clinical milestones for BGE-102 ● 1H 2026..